Startup profile for StandardX: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

StandardX funding, valuation and investors

Deep-tech isotope company launched with a £10 million seed round to build a scalable isotope refinery.

Keep track of StandardX

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

£10M · September 23, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · United Kingdom

Investors in latest funding

Lead: Vsquared Ventures , East X Ventures

Sources: latest funding Last verified: 2026-09-30

Overview

StandardX is building a scalable isotope refinery intended to increase supplies of rare isotopes used in medicine, research and fusion. The company announced its launch and a £10 million seed round on September 23, 2026, led by Vsquared Ventures and East X Ventures.

Why StandardX is interesting

A distinctive deep-tech financing tied to medical isotopes and fusion, with first-party disclosure and a clear seed-stage narrative.

Key facts

  • Sep 23, 2026: £10M seed
  • Company is building a scalable isotope refinery for medicine and fusion

Funding history (newest first)

Market / IPO context

Editorial / static context — not a live quote.

FAQs about StandardX

Practical answers founders, operators, and investors typically search for.

StandardX announced a £10 million seed round on September 23, 2026.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.